MA43848A - Composés deutérés pour le traitement d'hémopathies malignes, compositions et procédés associés - Google Patents

Composés deutérés pour le traitement d'hémopathies malignes, compositions et procédés associés

Info

Publication number
MA43848A
MA43848A MA043848A MA43848A MA43848A MA 43848 A MA43848 A MA 43848A MA 043848 A MA043848 A MA 043848A MA 43848 A MA43848 A MA 43848A MA 43848 A MA43848 A MA 43848A
Authority
MA
Morocco
Prior art keywords
procedures
treatment
deuterated compounds
associated compositions
malignant hemopathies
Prior art date
Application number
MA043848A
Other languages
English (en)
Inventor
Changfu Cheng
Chaoran Huang
Original Assignee
Neuform Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuform Pharmaceuticals Inc filed Critical Neuform Pharmaceuticals Inc
Publication of MA43848A publication Critical patent/MA43848A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA043848A 2015-10-21 2016-09-16 Composés deutérés pour le traitement d'hémopathies malignes, compositions et procédés associés MA43848A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562244267P 2015-10-21 2015-10-21

Publications (1)

Publication Number Publication Date
MA43848A true MA43848A (fr) 2018-11-21

Family

ID=58558146

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043848A MA43848A (fr) 2015-10-21 2016-09-16 Composés deutérés pour le traitement d'hémopathies malignes, compositions et procédés associés

Country Status (8)

Country Link
US (1) US9688659B2 (fr)
EP (1) EP3365336B1 (fr)
JP (1) JP6588647B2 (fr)
CN (1) CN107207469B (fr)
AU (1) AU2016340740B2 (fr)
CA (1) CA3002531C (fr)
MA (1) MA43848A (fr)
WO (1) WO2017069878A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110054614B (zh) * 2018-01-19 2021-12-28 南京圣和药业股份有限公司 三嗪类idh抑制剂的可药用盐及其制备方法
CN111662271B (zh) * 2019-03-08 2023-11-14 中国药科大学 具有idh突变体抑制活性的化合物及其制备方法与应用
US20230193336A1 (en) * 2020-03-16 2023-06-22 Double Rainbow Biosciences Inc. Enasidenib glycosides and methods of treating diseases associated with isocitrate dehydrogenase (idh) dysfunction
CN111592524B (zh) * 2020-05-20 2023-11-17 温州市天聚万迅信息科技有限公司 恩西德尼的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
EP1104760B1 (fr) * 1999-12-03 2003-03-12 Pfizer Products Inc. Composés de sulfamoylhétéroaryl-pyrazole comme analgésiques et agents anti-inflammatoires
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
CA2624179A1 (fr) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Inhibiteurs deuteries d'atpase h+,k+ gastrique ayant des proprietes therapeutiques renforcees
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
WO2011044019A1 (fr) * 2009-10-05 2011-04-14 Bristol-Myers Squibb Company Métabolites du (r)-1-(4-(4-fluoro-2-méthyl-1h-indol-5-yloxy)-5-méthylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol
KR101893112B1 (ko) * 2012-01-06 2018-08-30 아지오스 파마슈티컬스 아이엔씨. 치료학적으로 활성인 화합물 및 이의 이용 방법
WO2015003360A2 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
WO2015003355A2 (fr) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
TWI666208B (zh) * 2013-08-02 2019-07-21 美商阿吉斯藥品有限公司 治療活性化合物及其使用方法(三)
WO2015018060A1 (fr) * 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Formes cristallines de composés thérapeutiquement actifs et utilisation associée

Also Published As

Publication number Publication date
CA3002531A1 (fr) 2017-04-27
US9688659B2 (en) 2017-06-27
CN107207469B (zh) 2018-09-25
AU2016340740A1 (en) 2018-05-10
JP2018531279A (ja) 2018-10-25
EP3365336A1 (fr) 2018-08-29
CA3002531C (fr) 2020-08-18
JP6588647B2 (ja) 2019-10-09
AU2016340740B2 (en) 2018-07-19
EP3365336A4 (fr) 2018-11-21
EP3365336B1 (fr) 2023-07-26
WO2017069878A1 (fr) 2017-04-27
CN107207469A (zh) 2017-09-26
US20170114041A1 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
FR25C1001I2 (fr) Compositions d'anticorps pour le traitement de tumeurs
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
EP3390357A4 (fr) Composés de biarylmonobactame et procédés d'utilisation correspondants pour le traitement d'infections bactériennes
EP3630072A4 (fr) Procédés et compositions pour le traitement d'une somnolence excessive
MA42439A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
MA46836A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
EP3555077A4 (fr) Compositions et procédés pour le traitement du cancer
EP3368560A4 (fr) Variants du facteur viii à cpg réduit, compositions, procédés et utilisations pour le traitement d'affections hémostatiques
MA41044A (fr) Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
MA43283A (fr) Procédés et compositions pour le traitement du cancer
EP3390642A4 (fr) Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13
EP3317274A4 (fr) Utilisation de composés de chloroquine et de clémizole pour le traitement d'états pathologiques inflammatoires et cancéreux
EP3380200A4 (fr) Compositions pour le traitement des cheveux
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
EP3374350A4 (fr) Composés à base d'hydroxypyridinone et d'hydroxypyrimidinone pour le traitement d'infections bactériennes
MA48942A (fr) Composés thérapeutiques, compositions et procédés d'utilisation associés
EP3380063A4 (fr) Compositions pour le traitement des cheveux
EP3389673A4 (fr) Procédés et compositions pour l'administration de polynucléotides
EP3541379A4 (fr) Compositions pour le traitement de l'hypertension
EP3478284A4 (fr) Composés et compositions pour le traitement du cancer
EP3630080A4 (fr) Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer
EP3352755A4 (fr) Nouveaux composés, compositions et méthodes pour le traitement de troubles cutanés
EP3403099A4 (fr) Procédés et compositions pour le traitement du cancer
EP3307301A4 (fr) Immunothérapie à base d'interféron focalisée pour le traitement du cancer
EP3648773A4 (fr) Composés et procédés pour l'administration transmembranaire de molécules